MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2024, and provided a company update. "As we work towards upcoming SAB-142 milestones, I remain enthusiastic about our ongoing pr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39871 SAB BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) De ...

[FORM 8-K Filing Details](index=1&type=section&id=FORM%208-K%20Filing%20Details) This section details the registrant's identity, contact information, and securities filing status [Registrant Information](index=1&type=section&id=Registrant%20Information) This section provides the core identification details for SAB Biotherapeutics, Inc. as the registrant, including its legal name, jurisdiction of incorporation, and primary contact information - Registrant Name: **SAB BIOTHERAPEUTICS, INC.**[2](index=2&type=chunk) - Jurisdiction of Incorporation: **Delaware**[2](index=2&type=chunk) - Principal Executive Offices: **2100 East 54th Street North, Sioux Falls, South Dakota 57104**[2](index=2&type=chunk) - Registrant's Telephone Number: **605 679-6980**[2](index=2&type=chunk) [Securities and Filing Status](index=1&type=section&id=Securities%20and%20Filing%20Status) This section outlines the company's registered securities and confirms its status as an emerging growth company, indicating specific regulatory considerations Registered Securities | Title of each class | Symbol(s) | Name of each exchange on which registered | | :------------------ | :-------- | :---------------------------------------- | | Common stock, $0.0001 par value per share | SABS | The Nasdaq Stock Market LLC | | Warrants, each exercisable for one share of Common Stock | SABSW | The Nasdaq Stock Market LLC | - **SAB Biotherapeutics, Inc.** is an Emerging Growth Company[5](index=5&type=chunk) - The registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards[6](index=6&type=chunk) [Current Report Items](index=3&type=section&id=Current%20Report%20Items) This section details the company's financial results announcement and lists accompanying exhibits [Item 2.02 Results of Operations and Financial Condition](index=3&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) SAB Biotherapeutics, Inc. issued a press release on March 29, 2024, to announce its financial results for the year and quarter ended December 31, 2023, along with a corporate update. This press release is furnished as Exhibit 99.1 - Date of Report: **March 29, 2024**[2](index=2&type=chunk) - Press Release Date: **March 29, 2024**[7](index=7&type=chunk) - Content of Press Release: Financial results for the year and quarter ended **December 31, 2023**, and a corporate update[7](index=7&type=chunk) - Exhibit Reference: The press release is furnished as **Exhibit 99.1**[7](index=7&type=chunk) - Filing Status: The information in this item, including Exhibit 99.1, is furnished and not deemed 'filed' for Section 18 of the Exchange Act[8](index=8&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=3&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the exhibits accompanying the Form 8-K filing, which include the press release detailing financial results and the interactive data file for the cover page Exhibits Filed | Exhibit Number | Description | | :------------- | :----------------------------------------------------------------------- | | 99.1 | Press Release of the Company, dated March 29, 2024 | | 104 | Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document. | [SIGNATURES](index=4&type=section&id=SIGNATURES) This section confirms the official signing of the Form 8-K report by the authorized executive [Report Signatures](index=4&type=section&id=Report%20Signatures) The Form 8-K report was duly signed on behalf of SAB Biotherapeutics, Inc. by its Chief Executive Officer, Samuel J. Reich, on March 29, 2024 - Signatory: **Samuel J. Reich**[13](index=13&type=chunk) - Title: **Chief Executive Officer**[13](index=13&type=chunk) - Date of Signature: **March 29, 2024**[13](index=13&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39871 October 12 SAB BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Delaware 85-3899721 (State or other ...

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 (Mark One) For the transition period from ___________________ to ___________________ Commission File Number: 001-39871 (Exact Name of Registrant as Specified in its Charter) Delaware 85-3899721 (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39871 SAB BIOTHERAPEUTICS, INC. Indicate by check mark whether the registr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39871 SAB BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39871 | SAB BIOTHERAPEUTICS, INC. | | | --- | --- | | (Exact name of Registrant as specified in its Charter) | | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39871 SAB BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Del ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39871 SAB BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) De ...